Polen Capital Management
CRL icon

Polen Capital Management’s Charles River Laboratories CRL Stock Holding History

Polen Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,248
Closed -$784K – 122
2024
Q4 		$784K Sell
4,248
-1,256
-23% -$242K ﹤0.01% 113
2024
Q3 		$1.08M Sell
5,504
-211
-4% -$43.9K ﹤0.01% 101
2024
Q2 		$1.18M Sell
5,715
-345
-6% -$78.2K ﹤0.01% 97
2024
Q1 		$1.64M Sell
6,060
-268
-4% -$64K ﹤0.01% 92
2023
Q4 		$1.5M Buy
6,328
+1,323
+26% +$260K ﹤0.01% 101
2023
Q3 		$981K Buy
5,005
+50
+1% +$10.3K ﹤0.01% 94
2023
Q2 		$1.04M Sell
4,955
-514
-9% -$102K ﹤0.01% 92
2023
Q1 		$1.1M Sell
5,469
-219
-4% -$49.6K ﹤0.01% 89
2022
Q4 		$1.24M Buy
5,688
+1,038
+22% +$227K ﹤0.01% 85
2022
Q3 		$915K Sell
4,650
-35
-0.7% -$7.56K ﹤0.01% 81
2022
Q2 		$1M Buy
+4,685
New +$1.14M ﹤0.01% 80

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Polen Capital Management's CRL Position: Q1 2025 in Review

Polen Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 4,248 shares — an estimated $784K sold.

Polen Capital Management first reported a position in CRL in Q2 2022 and held it in 11 quarters. The position peaked at $1.64M in Q1 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Polen Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Polen Capital Management sold 4,248 Charles River Laboratories shares in Q1 2025, an estimated $784K.
  • Polen Capital Management first reported a position in Charles River Laboratories in Q2 2022 and held it in 11 quarters.
  • Polen Capital Management's Charles River Laboratories position peaked at $1.64M in Q1 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Polen Capital Management's 13F filing for Q1 2025, filed 12 May 2025.